Comprehensive biomarker testing can identify EGFR or other mutations in your lung cancer. Learn the benefits of testing and how it can help shape treatment.

Some non-small-cell lung cancers (NSCLC) have changes in a gene called EGFR. If your NSCLC has these mutations, your doctor likely will recommend treatment with targeted therapies that block EGFR.